Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method of treatment and pharmaceutical composition|
|Abstract:||The invention relates to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, myocardial infarction and its sequelae, supraventricular and ventricular arrhythmias, atrial fibrillation or atrial flutter, atherosclerosis, angina (whether stable or ustable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, hypertension in patients with NIDDM, secondary aldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), and stroke, comprising administering a therapeutically effective amount of combination of (i) the AT.sub.1 -antagonists valsartan or a pharmaceutically acceptable salt thereof and (ii) a Calcium channel blocker or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a mammal in need of such treatment and to corresponding pharmaceutical combination composition.|
|Inventor(s):||Webb; Randy Lee (Flemington, NJ), de Gasparo; Marc (Es Planches, CH)|
|Assignee:||Novartis AG (Basel, CH)|
|Filing Date:||Jul 08, 1999|
|Claims:||1. A method for the treatment or prevention of hypertension associated with diabetes comprising administering a therapeutically effective amount of a combination consisting essentially of (i) the AT.sub.1 -antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) the Calcium channel blocker verapamil or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier to a mammal in need thereof. |
2. A pharmaceutical combination composition consisting essentially of (i) the AT.sub.1 -antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) the Calcium channel blocker verapamil or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
3. A pharmaceutical combination composition as claimed in claim 2 for oral application, comprising of about 10 mg to about 200 mg of valsartan.
4. A pharmaceutical combination composition as claimed in claim 2 for oral application, comprising about 1.0 mg to about 180 mg of verapamil.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.